GlassScriptPhysician profile
Vijay Rao
NPI 1982725180
$26,094.38
in general payments reported to CMS, 2019-2025
66 companies · $3,012 in 2025
The $3,012 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,802 · 2020: $2,524 · 2021: $1,022 · 2022: $3,487 · 2023: $6,673 · 2024: $7,574 · 2025: $3,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,070 · Food and Beverage: $4,717 · Travel and Lodging: $3,053 · Education: $419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,070.00 |
| Food and Beverage | $4,717.11 |
| Travel and Lodging | $3,052.66 |
| Education | $418.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $5,462.98 | 2019-2024 | Kisqali |
| Gilead Sciences, INC. | $5,055.11 | 2019-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $4,767.16 | 2020-2025 | Tagrisso, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $1,786.48 | 2023-2025 | Opdivo, Opdualag |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,643.40 | 2019-2021 | |
| Aveo Pharmaceuticals, INC. | $1,093.06 | 2021-2024 | Fotivda |
| Celgene Corporation | $581.63 | 2021-2025 | Reblozyl, Inrebic, Breyanzi |
| Genzyme Corporation | $450.47 | 2021-2025 | |
| Tempus Ai, INC | $429.26 | 2024-2025 | Xt Cdx |
| Janssen Biotech, INC. | $406.45 | 2022-2025 | Rybrevant, Carvykti, Erleada |
| Alexion Pharmaceuticals, INC. | $329.58 | 2022-2024 | Ultomiris |
| Janssen Scientific Affairs, LLC | $274.52 | 2022-2025 | Erleada, Balversa, Akeega |
| Pfizer INC. | $225.79 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $213.49 | 2021-2023 | Imbruvica |
| Daiichi Sankyo INC. | $209.78 | 2021-2025 | Enhertu |
Show all 65 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijay Rao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.